DiaMedica Announces Positive Interim Results for DM199 Study

An update from Diamedica Therapeutics ( (DMAC) ) is now available.

On July 17, 2025, DiaMedica Therapeutics announced positive interim results from Part 1a of their Phase 2 study of DM199 for treating preeclampsia. The study showed statistically significant reductions in blood pressure and uterine artery pulsatility index, with no placental transfer, indicating a potential breakthrough in preeclampsia treatment. The results suggest that DM199 could offer a significant safety advantage for mothers and their babies, addressing a major unmet medical need.

The most recent analyst rating on (DMAC) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Diamedica Therapeutics stock, see the DMAC Stock Forecast page.

Spark’s Take on DMAC Stock

According to Spark, TipRanks’ AI Analyst, DMAC is a Neutral.

Diamedica Therapeutics faces significant financial hurdles with no revenue and rising net losses, leading to a low financial performance score. Technical analysis presents mixed signals, adding uncertainty. Despite this, the company’s optimistic guidance and significant progress in clinical trials offer some potential, reflected in a moderate earnings call score. However, the speculative nature of its valuation due to the absence of earnings and dividends remains a key risk.

To see Spark’s full report on DMAC stock, click here.

More about Diamedica Therapeutics

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for unmet medical needs, particularly in the area of preeclampsia, a serious pregnancy disorder. Their primary product, DM199, is a recombinant form of the KLK1 protein aimed at regulating blood pressure and vascular health.

Average Trading Volume: 187,654

Technical Sentiment Signal: Hold

Current Market Cap: $184.4M

Find detailed analytics on DMAC stock on TipRanks’ Stock Analysis page.